Coronary microvascular disease
Conditions
Interventions
Test group:Apply standard treatment+broadchest aerosol, sublingual spray, 3 press/time, 3 times a day
control group:Receive standard treatment (metoprolol succinate+nicorandil+diltiazem hydrochloride).
Sponsors
Xijing Hospita
Eligibility
Sex/Gender
All
Age
18 Years to 90 Years
Inclusion criteria
Inclusion criteria: (1) 18 years = age = 90 years (2) Diagnosed as CMVD without concomitant obstructive coronary artery disease and meeting the indications for broadchest aerosol medication use; (3) Diagnostic criteria for CMVD without concomitant obstructive coronary artery disease: symptoms of myocardial ischemia (symptoms of exertional or resting angina); no obstructive coronary artery disease (coronary artery stenosis<50% on coronary angiography or no or mild stenosis on coronary artery CTA); objective evidence of myocardial ischemia (Ischemic electrocardiogram changes occur during angina attacks; transient and reversible local wall motion abnormalities or perfusion defects/CFR less than 2.0 occur during stress SPECT examination); (4) Sign a written informed consent form.
Exclusion criteria
Exclusion criteria: (1) Individuals who are allergic to broad-breasted aerosols or their components (Asarum oil, sandalwood oil, Gao Liang Jiang oil, Piper longum oil, borneol), or any component of drugs; (2) Patients with severe autoimmune diseases or malignant tumors; (3) Patients with severe liver, kidney, brain, and lung dysfunction; (4) Patients with hyperthyroidism or hypothyroidism; (5) Patients with a history of chronic heart failure or cardiomyopathy (stress cardiomyopathy, hypertrophic cardiomyopathy, dilated cardiomyopathy, myocarditis, aortic stenosis, Anderson Fabry disease, myocardial amyloidosis); (6) Excluding non cardiac chest pain; (7) Pregnant or ready to conceive women; (8) Patient life expectancy = 12 months; (9) The researcher determined that the patient is not suitable to participate in this study due to other reasons; (10) Patients who are participating in other clinical trials but have not reached the main study endpoint deadline.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Microcirculatory function; | — |
Secondary
| Measure | Time frame |
|---|---|
| Assessment of angina symptoms;quality of life;Exercise tolerance;major adverse cardiac events;Anxiety and depression;Inflammatory factor levels;Platelet distribution width;D-Dimer; | — |
Countries
the People's Republic of China
Contacts
Public ContactLi Chengxiang
Xijing Hospital
Outcome results
None listed